血泌尿素II在心力衰竭中的作用
A Mark Richards1, M Gary Nicholls, John G Lainchbury
1Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand. mark.richards@cdhb.gov.nz
Lancet (London, England)
|September 21, 2002
概括
在患有心力衰竭的患者中,血泌尿素II水平显著升高. 需要进一步的研究来了解尿素II在心力衰竭病理生理学中的特定作用.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 心脏衰竭研究研究
背景情况:
- 尿素II具有强大的血管收缩和负义无otropic 特性.
- 这些生理效应表明,它可能与循环调节和心力衰竭有关.
- 尿素II在心力衰竭病理生理学的确切作用在很大程度上仍未确定.
研究的目的:
- 调查尿素II在心力衰竭中的潜在作用.
- 测量和比较心力衰竭患者和健康对照者的血尿素II度.
主要方法:
- 开发一种敏感和特定的放射性免疫试验 (RIA) 尿素II.
- 在心力衰竭患者队列和对照组中测量血尿素II水平.
主要成果:
- 与对照组 (平均1.9 pmol/L) 相比,心力衰竭患者 (平均3.9 pmol/L) 的血尿素II水平显著更高.
- 两组血中尿素II度的差异在统计学上是显著的 (p<0.0001).
结论:
- 这项研究表明,心力衰竭患者血尿素II显著升高.
- 这些发现凸显了尿素II作为潜在的生物标志物或导致心力衰竭的因素.
- 需要进一步的研究,以阐明尿素II在心力衰竭中的具体机制和临床影响.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

